Source comparison
Side-by-Side Comparison
Mechanism MC4R agonist (central nervous system) PDE5 inhibitor (peripheral vascular) Evidence Grade A A+ Action Site Central (brain/hypothalamus) Peripheral (smooth muscle/vasculature) Route Subcutaneous injection Oral tablet Typical Dose 1.75 mg SC (as needed
This comparison does not assign a generated winner or score.
- Mechanism
- MC4R agonist (central nervous system)
- PDE5 inhibitor (peripheral vascular)
- Evidence Grade
- A
- A+
- Action Site
- Central (brain/hypothalamus)
- Peripheral (smooth muscle/vasculature)
- Route
- Subcutaneous injection
- Oral tablet
- Typical Dose
- 1.75 mg SC (as needed)
- 5 - 20 mg oral (as needed or daily)
- Onset
- ~45-60 minutes
- ~30-60 minutes
- Duration
- ~6-12 hours
- ~24-36 hours
- Best For
- Desire/arousal disorders, female HSDD
- Erectile dysfunction, BPH
- FDA Status
- FDA-approved (Vyleesi for female HSDD)
- FDA-approved (ED, BPH)
- Works for Women
- Yes (primary indication)
- Not FDA-approved for women
- Cost (research grade)
- $$
- $ (generic available)